The gleaming white table in the boardroom of Oxford Biomedica’s headquarters is so enormous and heavy it can only be removed by taking down the windows and lifting it with a crane. The carpet feels soft, squishy – expensive.
AstraZeneca (NASDAQ: AZN) awaits U.S. Emergency Use Authorization for its COVID-19 antibody therapy as a prophylaxis. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss how effective AstraZeneca might be in competing against antibody therapies marketed by COVID-19 antibody therapies already on the market.
Former U.S. Commerce Sec. Gary Locke weighs in on the global vaccine equity debate and how the U.S. can better respond to the ongoing pandemic.